Qiagen NV, Venlo, the Netherlands (NASDAQ:QGEN/XETRA:QIA)
A leading global provider of sample and assay technologies used to transform biological materials into molecular information,marketing more than 500 products around the world, selling both consumable kits and automation systems.
Evaluate strategic options for the Pecura veterinary product technology portfolio; spin-out business unit with third party funding vs. outright sale of the assets.
Merial SA, a world-leading animal health company producing pharmaceutical products and vaccines for livestock, pets and wildlife. Merial is today the animal health division of Sanofi SA (NYSE: SNY / NYSE EURONEXT: SAN).
Sale of portfolio of certain veterinary rights to a novel class of drugs based on CpG dinucleotides, presented in synthetic oliogodeoxynucleotides for use in livestock and companion animals. Financial terms were not disclosed.
Acted as Financial Advisor to the Board of Directors and management.
- Prepared dual-track marketing process and compiled due diligence materials.
- Devised and managed strategic sales process maintaining competitive tension through-out the process.
- Spearheaded negotiations with several interested parties and ensured favourable financial outcome for shareholders and stakeholders.
N.B. Consulting services performed prior to the formation of CATALYSIS CAPITAL PARTNERS LTD. and authorisation and regulation by FCA UK
